South Korean company Celltrion Inc has received approval for Phase 3 clinical trials for an experimental treatment for COVID-19, the antibody drug CT-P59. This drug targets the surface of the virus and blocks it from attaching to human cells. Celltrion has stated that the third stage trials will be carried out on at least 1,000 asymptomatic COVID-19 patients as well as those who have come into close contact with them.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape